Clinical Genetic Test
offered by
GTR Test Accession:
Help
GTR000593816.3
CAP
Last updated in GTR: 2021-08-24
View version history
GTR000593816.3, last updated: 2021-08-24
GTR000593816.2, last updated: 2021-08-23
GTR000593816.1, last updated: 2021-08-20
Last annual review date for the lab: 2023-07-14
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Pre-symptomatic;
Risk Assessment; ...
Conditions (6):
Help
Autism spectrum disorder; Cerebellar ataxia; Fragile X syndrome; ...
Genes (1):
Help
FMR1 (Xq27.3)
Methods (2):
Help
Molecular Genetics - Methylation analysis: Methylation-specific PCR; ...
Target population: Help
Individuals with clinical features overlapping with Fragile X syndrome (e.g. …
Clinical validity:
Help
This assay will detect the CGG trinucleotide expansion in >99% …
Clinical utility:
Help
Establish or confirm diagnosis;
Reproductive decision-making
Ordering Information
Offered by:
Help
Test short name:
Help
Fragile X
Specimen Source:
Help
- Cord blood
- Isolated DNA
- Peripheral (whole) blood
- View specimen requirements
Who can order: Help
- Genetic Counselor
- Health Care Provider
- Licensed Physician
- Nurse Practitioner
Test Order Code:
Help
FRAGX
View other test codes
View other test codes
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
Samples can be accepted 7 days a week (Monday - Sunday). All samples must be labeled with minimum of two patient identifying information (e.g. Patient Name and Date of Birth). Please submit all samples with a completed test requisition form.
Order URL
Order URL
Test development:
Help
Manufactured (research use only; not FDA-reviewed)
Informed consent required:
Help
No
Test strategy:
Help
PCR analysis will be performed to evaluate the number of CGG repeats. For diagnostic testing, if a premutation (55-200 repeats) or a full mutation (>200 repeats) is detected by PCR, then reflex to methylation analysis will be automatically performed.
Pre-test genetic counseling required:
Help
No
Post-test genetic counseling required:
Help
No
Recommended fields not provided:
Lab contact for this test
Conditions
Help
Total conditions: 6
| Condition/Phenotype | Identifier |
|---|
Test Targets
Genes
Help
Total genes: 1
| Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
|---|
Methodology
Total methods: 2
Method Category
Help
Test method
Help
Instrument *
Methylation analysis
Methylation-specific PCR
Targeted variant analysis
Tetra-nucleotide repeat by PCR or Southern Blot
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis;
Pre-symptomatic;
Risk Assessment;
Screening
Clinical validity:
Help
This assay will detect the CGG trinucleotide expansion in >99% of individuals with Fragile X syndrome and other FMR1-related disorders.
View citations (2)
- Hunter JE, Berry-Kravis E, Hipp H, Todd PK. Disorders. 1998 Jun 16 [updated 2019 Nov 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301558.
- https://www.ncbi.nlm.nih.gov/books/NBK1384
Clinical utility:
Help
Establish or confirm diagnosis
Reproductive decision-making
View citations (2)
- Hunter JE, Berry-Kravis E, Hipp H, Todd PK. Disorders. 1998 Jun 16 [updated 2019 Nov 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301558.
- https://www.ncbi.nlm.nih.gov/books/NBK1384
Reproductive decision-making
View citations (2)
- Hunter JE, Berry-Kravis E, Hipp H, Todd PK. Disorders. 1998 Jun 16 [updated 2019 Nov 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301558.
- https://www.ncbi.nlm.nih.gov/books/NBK1384
Target population:
Help
Individuals with clinical features overlapping with Fragile X syndrome (e.g. intellectual disability, autism spectrum disorder, etc.) or other FMR-1 related disorders (e.g. late onset progressive cerebellar ataxia, intention tremor, premature ovarian failure, etc.).
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
VUS and novel variants will be interpreted by trained variant analysis team member and a lab director using the current ACMG variant classification criteria.
VUS and novel variants will be interpreted by trained variant analysis team member and a lab director using the current ACMG variant classification criteria.
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
No.
No.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Yes. No systemic re-evaluation of previously reported variants/findings are currently performed. However, if the same variant/finding is identified in another patient and current assessment results in change in variant classification/interpretation, then the laboratory will recontact the ordering provider and issue an updated report.
Yes. No systemic re-evaluation of previously reported variants/findings are currently performed. However, if the same variant/finding is identified in another patient and current assessment results in change in variant classification/interpretation, then the laboratory will recontact the ordering provider and issue an updated report.
Recommended fields not provided:
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
Analytical Sensitivity >99%. Analytical Specificity >99%. Accuracy/Precision >99%.
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
College of American Pathologists, CAP
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
College of American Pathologists, CAP
VUS:
Laboratory's policy on reporting novel variations
Help
Unusual or clinically significant novel variants will be communicated to the ordering provider via telephone call or email communication.
Unusual or clinically significant novel variants will be communicated to the ordering provider via telephone call or email communication.
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Category:
Not Applicable
Additional Information
Clinical resources:
Practice guidelines:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.